press release

May 5, 2017

— Results from Phase I Trial of ALN PCS Demonstrate Rapid, Dose Dependent, and Durable Reduction of Plasma PCSK9 of up to 84% and Serum LDL Cholesterol of up to 57% — — New Paper Documents First Human Proof of Concept for an RNAi Therapeutic Toward a Clinically Validated Endpoint — CAMBRIDGE, Mass. (BUSINESS WIRE) Alnylam ...

press release

May 5, 2017

CAMBRIDGE, Mass. (BUSINESS WIRE) Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that it will webcast its upcoming R&D Day live on the News & Investors section of the company's website, www.alnylam.com. Alnylam scientists and management will review progress with the company's Alnylam 5×15 pipeline for the development ...

press release

May 5, 2017

— Continued to Execute on "Alnylam 5x15" Product Strategy, Positioning Company for Data Rich Period over Next Several Months — — Formed Strategic Alliance with The Medicines Company to Develop and Commercialize ALN PCS, an RNAi Therapeutic Targeting PCSK9 for the Treatment of Hypercholesterolemia — — Completed Successful Public Offering of Stock; Maintained Strong Balance Sheet with ...

press release

May 5, 2017

.bwcellpaddingbottom1 {padding bottom: 2.0px} .bwcellpaddingbottom3 {padding bottom: 4.0px} .bwcellpaddingleft0 {padding left: 0.0px} .bwcellpaddingleft3 {padding left: 15.0px} .bwcellpaddingleft4 {padding left: 20.0px} .bwcellpaddingleft7 {padding left: 35.0px} .bwcellpaddingright0 {padding right: 0.0px} .bwcellparagraphmargin {margin bottom: 0px; margin top: 0px} .bwdoublebottomborder {border bottom: double black 2.25pt} .bwlistitemmarginbottom {margin bottom: 10.0px} .bwmarginleft1 {margin left: 30.0px} .bwsinglebottomborder {border bottom: solid black 1.0pt} .bwtablebottommargin {margin bottom: 10.0px} .bwtextaligncenter {text ...

press release

May 5, 2017

CAMBRIDGE, Mass. (BUSINESS WIRE) Nov. 12, 2009 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, is providing an update on its RNAi pipeline, platform, and technology at its R&D Day being held in New York today. Alnylam scientists and management will be joined by two guest speakers: Professor Allan Glanville, Director of Thoracic Medicine and Medical Director Lung ...

press release

May 5, 2017

— Continued to Execute on "Alnylam 5x15™" Product Strategy with Positive Clinical Data in Multiple RNAi Therapeutic Programs Including ALN TTR02 for Treatment of Transthyretin (TTR) Mediated Amyloidosis (ATTR) and ALN PCS for Treatment of Hypercholesterolemia — — Advanced Proprietary Conjugate Delivery Platform Enabling Subcutaneous Delivery of RNAi Therapeutics Towards the Clinic, Including ALN TTRsc for ...

press release

May 5, 2017

Alnylam Presents New Pre Clinical Data on RNAi Therapeutics at Oligonucleotides Therapeutics Society (OTS) MeetingCAMBRIDGE, Mass. (BUSINESS WIRE) Nov. 5, 2009 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it presented new data related to its overall delivery research efforts including the rational design of Mimetic Lipoprotein Particles, or MLPs, a novel technology for the ...

press release

May 5, 2017

CAMBRIDGE, Mass. and CARLSBAD, Calif., November 30, 2008 – Regulus Therapeutics LLC, a joint venture between Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) formed to discover, develop, and commercialize microRNA based therapeutics, announced today the publication of new research in the journal Nature on the role of a microRNA, known as miR 21, in heart failure(1). The ...

press release

May 5, 2017

Alnylam and Medtronic Present New Late Stage Pre clinical Data on ALN HTT, an RNAi Therapeutic for the Treatment of Huntington's Disease New Data Demonstrate Broad CNS Distribution and Robust Therapeutic Silencing of Gene Responsible for Huntington’s Disease Continuous 28 Day CNS Infusion of ALN HTT Found to be Safe and Well Tolerated VANCOUVER, B.C. (BUSINESS WIRE) Sep. 15, 2009 ...

press release

May 5, 2017

Alnylam and Collaborators Publish New Research on the In Vivo Mechanisms for Systemic Delivery of RNAi TherapeuticsCAMBRIDGE, Mass. (BUSINESS WIRE) Sept. 17, 2007 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced the publication of a study in the journal Nature Biotechnology by Alnylam and scientific collaborators from the Swiss Federal Institute of Technology (ETH) related to mechanisms ...